Clinical trials · New York
Cancer Patients clinical trials in New York
We’re tracking 305 recruiting cancer patients studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Harrison, New YorkAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
New York, New YorkAges 18 years+ - NCT06892691Recruiting
Pleuroscopy vs. Thoracentesis for Possible Cancer-Related Fluid in Lung
This trial compares two approaches to diagnosing fluid around the lung that may be caused by cancer: starting with a camera scope (pleuroscopy) versus starting with a needle drainage (thoracentesis). It aims to see which method leads to a quicker and clearer diagnosis.
New York, New YorkAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
New York, New YorkAges 18 years+ - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Rochester, New YorkAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
New York, New YorkAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
The Bronx, New YorkAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
New York, New YorkAges 18 years+ - NCT05292521Recruiting
Quality-of-life program to help early lung cancer decisions
This trial tests a quality-of-life support program meant to help people with early-stage lung cancer think through their treatment choices. It may help you feel more informed and more confident about deciding between treatments like surgery and SBRT.
Buffalo, New YorkAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Bay Shore, New YorkAges 18–60 - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Webster, New YorkAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
New York, New YorkAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Westbury, New YorkAges 18 years+ - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
New York, New YorkAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Flushing, New YorkAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
New York, New YorkAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
New York, New YorkAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Lake Success, New YorkAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
New York, New YorkAges 18 years+ - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT06615635Recruiting
Radiation device trial for skin cancer in patients with weak immune systems
This trial tests a special radiation device (DaRT) placed directly into skin cancer tumors. It is designed for patients with weakened immune systems (immunocompromised) who have a single skin cancer lesion on the skin (not spread elsewhere).
Cooperstown, New YorkAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Mineola, New YorkAges 18 years+
Cancer Patients trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer patients studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- Columbia University Irving Medical Center · 4 studies
- NYU Langone Health · 4 studies
- Roswell Park Cancer Institute · 4 studies
- University of Rochester · 4 studies
- Weill Cornell Medicine · 4 studies
- Mount Sinai Health System · 3 studies
- NYU Langone Hospital - Long Island · 3 studies
What taking part in a cancer patients study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer Patients trials in other states
Common questions
- Are there cancer patients clinical trials in New York?
- Yes. We're currently tracking 305 recruiting cancer patients studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer patients study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer patients trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer patients studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.